At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 196 enrolled
Drug / intervention
LYR-210 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults
In Brief
A Phase 3 clinical trial evaluating LYR-210, Sham procedure control, and 1 other intervention for Chronic Sinusitis and Chronic Rhinosinusitis (Diagnosis). Completed, enrolled 196 participants across 55 sites in 5 countries.
Detailed Summary
Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Czechia, Poland, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedFeb 2022
Primary CompletionMar 2024
Study CompletionSep 2024
TodayJul 2026
First PostedFeb 2, 2022
Enrollment StartJan 27, 2022
Primary CompletionMar 4, 2024
Study CompletionSep 16, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.4 years ago
Interventions
LYR-210drug
LYR-210 drug matrix (mometasone furoate)
Sham procedure controldrug
Sham procedure control
Background Therapyother
Daily Saline Irrigation